Quick Answer
Allogene Therapeutics, Inc. reported Earnings Per Share Diluted of $0.87 (loss) per share for the year ending 2025.
- Allogene Therapeutics, Inc. showed an increase of +34.1% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Allogene Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Allogene Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 52.5%.
- Historical annual values: Fiscal year 2025: $0.87 (loss) per share | Fiscal year 2024: $1.32 (loss) per share | Fiscal year 2023: $2.09 (loss) per share | Fiscal year 2022: $2.38 (loss) per share | Fiscal year 2021: $1.34 (loss) per share | Fiscal year 2020: $2.08 (loss) per share | Fiscal year 2019: $1.83 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: